Anti cell proliferative

ASX
LCT 0.041   Last updated EOD 10th December 2018
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

Anti Cell Proliferative

Target: Glioma

 

Gliomas are the most common primary brain tumour, making up 81 percent of malignant brain tumours. Although relatively rare, they are highly malignant. Glioblastoma, the most common glioma, has a 5-year relative survival of less than 5 percent. There is currently no cure.

 

Working with Sir Richard Faull’s Centre for Brain Research, we are evaluating compounds that prevent human glioma cells from proliferating in vitro. The next step is to confirm the lead compound and test in an animal model of glioma. 

 

If successful, that compound would be further developed to undertake the first clinical trial in patients. The investigator would be neurosurgeon Mr Patrick Schweder at Auckland Hospital.

PRINT PAGE print-icon
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.